Media Inquiries: For all MAVA media inquiries, please contact us at 703-506-9300 or email firstname.lastname@example.org.
Check back regularly for news, coverage, and announcements about MAVA.
The funds from the loan facility will support the Company’s efforts to expand its manufacturing infrastructure.
Nanotherapeutics’ core competencies are in development and cGMP manufacture of pre-clinical and clinical stage biopharmaceutical products. The Company provides a full range of drug development services and intends to further capitalize on its capabilities through partnerships with government and established companies, as well as continuing to fund the development of its internal pipeline.